Post-Market Study to Assess Outcomes of Patients Treated With AFX System Compared to Other EVAR Devices
A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 455 participants.
Also called NCT02407457
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Not applicable
- Enrolled
- 455 participants
- Sponsor
- Registry
-
NCT02407457
-
- Other papers using this trial's data
- Five-year results of the LEOPARD trial of commercially available endografts
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT02407457. Randomized; no masking; primary purpose treatment. Start 2015-03 (actual); primary completion 2018-10 (actual). Results posted on 2020-09-21.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Post-Market Study to Assess Outcomes of Patients Treated With AFX System Compared to Other EVAR Devices
- Acronym
- LEOPARD
- Condition
- Abdominal Aortic Aneurysm
- Intervention (Device)
- AFX EVAR AAA Graft System
- Intervention (Device)
- FDA Approved EVAR AAA Graft Systems
- Lead sponsor
- Endologix
Record details
- Record id
cardio:ct-nct02407457- Content hash
c7018788a15d2c94f85e8c6bde978d582b4a82c3604841d803d47775483e0099